Regeneron Pharmaceuticals (REGN) FCF Payout Ratio (2025 - 2026)
Regeneron Pharmaceuticals' (REGN) quarterly FCF Payout Ratio came in at 0.12 in Q1 2026, little changed year-on-year from 0.11 in Q1 2025, and up 14.67% quarter-over-quarter from 0.1 in Q4 2025.
Regeneron Pharmaceuticals (REGN) FCF Payout Ratio (2025 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' FCF Payout Ratio history runs 2 years deep, the most recent figure standing at 0.12 for Q1 2026.
- On a quarterly basis, FCF Payout Ratio changed 0.27% year-over-year to 0.12 in Q1 2026; TTM through Mar 2026 was 0.09, a 200.93% increase from a year earlier, with the FY2025 full-year figure at 0.09, changed N/A from the prior year.
- FCF Payout Ratio grew to 0.12 in Q1 2026 per REGN's latest filing, from 0.1 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 0.12 in Q1 2026 and bottomed at 0.08 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.12 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.11 |